Burning rock received breakthrough device designation from china's nmpa for its multi-cancer early detection test

Guangzhou, china, oct. 15, 2023 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”) is pleased to announce that followed an earlier breakthrough device designation granted by the us food and drug administration (fda) for its overc™ multi-cancer detection blood test (mcdbt) in january 2023, its overc™ mcdbt has been granted breakthrough device designation by the china national medical products administration(nmpa), which represents the only test globally that has received breakthrough device designation from both us fda and china nmpa. overc™ mcdbt is intended for early detection of multiple cancer types in adults of either sex, aged 50-75 years old, at average risk for cancer.
BNR Ratings Summary
BNR Quant Ranking